https://www.selleckchem.com/products/rgt-018.html
We investigated changes in ARDS severity and associations with outcome in COVID-19 ARDS patients. We compared outcomes in patients with ARDS classified as 'mild', 'moderate' or 'severe' at calendar day 1, and after reclassification at calendar day 2. The primary endpoint was 28-day mortality. We also identified which ventilatory parameters had an association with presence of severe ARDS at day 2. We repeated the analysis for reclassification at calendar day 4. Of 895 patients, 8.5%, 60.1% and 31.4% had mild, moderate and severe ARDS at
Like
Comment
Share
